Dabur India Limited has informed the Exchange about Transcript
DABUR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dabur reported FY25 consolidated revenue of INR 12,563 crores (up 3.6% in constant currency) and PAT of INR 1,768 crores. Q4 was soft with consolidated revenue up just 2.1% in CC (0.6% in INR) as the India business declined ~3.4%, hit by high bases in HPC, weak urban demand, delayed winters impacting Honey and Chyawanprash, and competitive intensity in beverages. Standalone gross margin contracted ~247 bps in Q4 due to 4.5-5% input inflation versus only 3.5% pricing taken. Management, working with McKinsey, unveiled a 7-pillar Vision strategy targeting sustainable double-digit top and bottom-line CAGR by FY28, with focus on premiumization, M&A in healthcare/wellness, and exiting underperforming categories like tea, diapers, sanitizers, Vita, and breakfast cereals (under 1% of revenue). FY26 guidance points to high single-digit to near double-digit value growth, with new launches mandated to be margin accretive.
Near-term results were weak with margin contraction and India business decline, which may weigh on the stock. However, the strategic reset, premiumization roadmap, M&A ambitions, and explicit margin-accretive guardrails signal management's focus on long-term profitable growth, which could support a gradual re-rating if execution improves.